decitabine
Showing 1 - 25 of 220
AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)
Recruiting
- AML
- MDS
- Decitabine
- Venetoclax
-
Tuebingen, Baden-Wuerttemberg, GermanyUniversity Hospital
Nov 30, 2023
Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)
Not yet recruiting
- Poor Graft Function
- Decitabine
- +3 more
- (no location specified)
Jun 8, 2023
Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)
Not yet recruiting
- Myeloid Malignancy
- Acute Myeloid Leukemia
- Venetoclax
- Decitabine
-
Cleveland, OhioUniversity Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023
Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)
Not yet recruiting
- Ovarian Cancer
- Decitabine
- +3 more
-
Maywood, IllinoisLoyola University Medical Center
Aug 1, 2023
Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Cladribine
- +4 more
- (no location specified)
Mar 1, 2023
Healthy Trial in San Antonio (Decitabine, Tetrahydrouridine)
Recruiting
- Healthy
- Decitabine
- Tetrahydrouridine
-
San Antonio, TexasWorldwide Clinical Trails Early Phase Services
Apr 14, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,
Active, not recruiting
- Acute Myeloid Leukemia
- +5 more
- Decitabine
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Recurrent Acute Myeloid Leukemia Trial in Nashville (Venetoclax, Decitabine, Cedazuridine)
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Venetoclax
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Mar 22, 2023
Poor Graft Function Trial (decitabine, umbilical cord blood, Granulocyte-colony stimulating factor)
Not yet recruiting
- Poor Graft Function
- decitabine
- +4 more
- (no location specified)
Dec 29, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Refractory Aplastic Anemia Trial in Tianjin (Decitabine)
Terminated
- Refractory Aplastic Anemia
- Decitabine
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Aug 25, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)
Recruiting
- Recurrent Leukemia
- Refractory Leukemia
- Decitabine
- Tegavivint
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)
Recruiting
- Myelodysplastic Syndromes
- MDS/MPN Crossover Syndromes
- 5-azacytidine
- Decitabine
-
Cleveland, OhioCleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022
Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)
Not yet recruiting
- Acute Myeloid Leukemia
- +6 more
- Decitabine
- Filgrastim
-
Boston, Massachusetts
- +1 more
Mar 31, 2023
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,
Completed
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Acute Myelogenous Leukemia Trial in Rochester (Decitabine)
Completed
- Acute Myelogenous Leukemia
- Decitabine
-
Rochester, New YorkUniversity of Rochester
Jul 1, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- STAT Inhibitor OPB-111077
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, MDS Trial in Minneapolis, Saint Louis, Rochester (Decitabine,
Completed
- Acute Myeloid Leukemia
- +2 more
- Decitabine
- +2 more
-
Minneapolis, Minnesota
- +2 more
Nov 2, 2022
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Decitabine
- +3 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 22, 2023
Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)
Active, not recruiting
- Acute Myeloid Leukemia
- Decitabine
- talazoparib
-
Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022
Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)
Recruiting
- Leukemia
- Cladribine
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 23, 2022